Large pharma companies reduced headcounts by more than 22K in 2025 as $300B patent cliff looms

headcount, reduction, revenue per employee

Large pharmaceutical companies, each with at least $20 billion in 2025 revenue, collectively reduced their workforces by more than 22,000 employees last year.  Among the 17 largest pharma companies analyzed in a Fierce Pharma review of annual reports, only five logged a head count increase in 2025…

Mar 23^rd • 10 mins read

Transforming oncology: Five frontiers driving progress in cancer care

Thought Leadership, Oncology

From biomarker-driven breakthroughs to AI-powered early detection and a renewed commitment to equity and patient centricity, the past 12 months have seen major strides across cancer research, treatment, and communication. At Inizio, we’ve had a front-row seat to this transformation, supporting…

May 16^th • 5 mins read

New Realities of Phase I Clinical Trials in the Era of

durvalumab, durvalumab experience, clinical trials, immunotherapy

The development of cancer immunotherapy, particularly durvalumab, has progressed rapidly due to innovative strategies, such as novel study designs. Durvalumab, an anti-PD-L1 monoclonal antibody, was developed by AstraZeneca starting in 2012, with initial trials leading to its accelerated appr…

Oct 7^th • 5 mins read